Literature DB >> 6992919

Absence of blood-pressure lowering effect of captopril in anephric patients.

B R Leslie, D B Case, J F Sullivan, E D Vaughan.   

Abstract

Captopril, an orally active inhibitor of angiotensin-I-converting enzyme, was administered in a single dose to five anephric patients who had extremely low plasma renin activities. The drug did not lower blood pressure or significantly alter plasma renin activity in any patient but increased mean arterial pressure slightly in three. These results suggest that the blood-pressure lowering effect of captopril depends on an active renal renin-angiotensin system. Though additional mechanisms, such as accumulation of vasodilator kinins resulting from kininase II inhibition, may also contribute to captopril's action, these mechanisms apparently require the presence of the kidney to have a clinically detectable effect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992919      PMCID: PMC1601200          DOI: 10.1136/bmj.280.6221.1067

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  14 in total

1.  Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme.

Authors:  E D Vaughan; R M Carey; C R Ayers; M J Peach
Journal:  J Clin Endocrinol Metab       Date:  1979-05       Impact factor: 5.958

2.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

3.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

4.  Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor.

Authors:  H Thurston; J D Swales
Journal:  Circ Res       Date:  1978-05       Impact factor: 17.367

5.  Inhibition of angiotensin conversion and prevention of renal hypertension.

Authors:  E D Miller; A I Samuels; E Haber; A C Barger
Journal:  Am J Physiol       Date:  1975-02

6.  Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.

Authors:  C I Johnston; J A Millar; B P McGrath; P G Matthews
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

7.  Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats.

Authors:  P Jaeger; R K Ferguson; H R Brunner; E J Kirchertz; H Gavras
Journal:  Kidney Int       Date:  1978-04       Impact factor: 10.612

Review 8.  Conversion of angiotensin I to angiotensin II.

Authors:  E G Erdös
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

9.  Accentuated vascular and endocrine response to SQ 20881 in hypertension.

Authors:  G H Williams; N K Hollenberg
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

10.  Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J I Drayer; R P White; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

View more
  4 in total

1.  Inhibitors of angiotensin I converting enzyme for treating hypertension.

Authors: 
Journal:  Br Med J       Date:  1980-09-06

2.  Hormonal and blood pressure changes during converting enzyme inhibition by teprotide.

Authors:  M J VandenBurg; V L Sharman; J J Morton; G H Williams; F P Marsh
Journal:  Postgrad Med J       Date:  1981-05       Impact factor: 2.401

Review 3.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

4.  Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.

Authors:  Ahmed M Shaman; Brendan Smyth; Clare Arnott; Suetonia C Palmer; Anastasia S Mihailidou; Meg J Jardine; Martin P Gallagher; Vlado Perkovic; Min Jun
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 8.237

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.